Search Results - "Carr, Donna"

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam by Bhagunde, Pratik, Zhang, Zufei, Racine, Fred, Carr, Donna, Wu, Jin, Young, Katherine, Rizk, Matthew L.

“…•The impact of relebactam concentration on imipenem susceptibility is described.•The PK/PD driver for relebactam is fAUC/MIC.•A relebactam fAUC/MIC ratio of…”
Get full text

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model by Wu, Jin, Racine, Fred, Wismer, Michael K, Young, Katherine, Carr, Donna M, Xiao, Jing C, Katwaru, Ravi, Si, Qian, Harradine, Paul, Motyl, Mary, Bhagunde, Pratik R, Rizk, Matthew L

“…Resistance to antibiotics among bacterial pathogens is rapidly spreading, and therapeutic options against multidrug-resistant bacteria are limited. There is an…”
Get full text

Development of a fully automated platform for agar-based measurement of viable bacterial growth by Squadroni, Brian, Newhard, William, Carr, Donna, Trinh, Huong, Racine, Fred, Zuck, Paul, Howell, Bonnie, Hazuda, Daria J., Cassaday, Jason

“…Dynamic in vitro antibacterial studies provide valuable insight on effective dosing strategies prior to translating to in vivo models. Frequent sampling is…”
Get full text

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules by Ashar, Hena R., James, Linda, Gray, Kimberly, Carr, Donna, Black, Stuart, Armstrong, Lydia, Bishop, W. Robert, Kirschmeier, Paul

“…Human tumor cell lines that are sensitive to the effects of farnesyl transferase inhibitors accumulate in G2 → M (except for cells with an activated Ha-ras…”
Get full text

The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines by Ashar, Hena R., James, Linda, Gray, Kimberly, Carr, Donna, McGuirk, Marnie, Maxwell, Eugene, Black, Stuart, Armstrong, Lydia, Doll, Ronald J., Taveras, Arthur G., Bishop, W.Robert, Kirschmeier, Paul

“…SCH 66336 is a potent farnesyl transferase inhibitor (FTI) in clinical development. It efficiently prevents the membrane association of H-ras, but not K- or…”
Get full text

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I by Zhang, F L, Kirschmeier, P, Carr, D, James, L, Bond, R W, Wang, L, Patton, R, Windsor, W T, Syto, R, Zhang, R, Bishop, W R

“…Ras proteins are small GTP-binding proteins which are critical for cell signaling and proliferation. Four Ras isoforms exist: Ha-Ras, N-Ras, Ki-Ras4A, and…”
Get full text

Selective small-molecule inhibition of an RNA structural element by Howe, John A., Wang, Hao, Fischmann, Thierry O., Balibar, Carl J., Xiao, Li, Galgoci, Andrew M., Malinverni, Juliana C., Mayhood, Todd, Villafania, Artjohn, Nahvi, Ali, Murgolo, Nicholas, Barbieri, Christopher M., Mann, Paul A., Carr, Donna, Xia, Ellen, Zuck, Paul, Riley, Dan, Painter, Ronald E., Walker, Scott S., Sherborne, Brad, de Jesus, Reynalda, Pan, Weidong, Plotkin, Michael A., Wu, Jin, Rindgen, Diane, Cummings, John, Garlisi, Charles G., Zhang, Rumin, Sheth, Payal R., Gill, Charles J., Tang, Haifeng, Roemer, Terry

“…Riboswitches are non-coding RNA structures located in messenger RNAs that bind endogenous ligands, such as a specific metabolite or ion, to regulate gene…”
Get full text

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors by Morris, Erick J, Jha, Sharda, Restaino, Clifford R, Dayananth, Priya, Zhu, Hugh, Cooper, Alan, Carr, Donna, Deng, Yongi, Jin, Weihong, Black, Stuart, Long, Brian, Liu, Jenny, Dinunzio, Edward, Windsor, William, Zhang, Rumin, Zhao, Shuxia, Angagaw, Minilik H, Pinheiro, Elaine M, Desai, Jagdish, Xiao, Li, Shipps, Gerald, Hruza, Alan, Wang, James, Kelly, Joe, Paliwal, Sunil, Gao, Xiaolei, Babu, Boga Sobhana, Zhu, Liang, Daublain, Pierre, Zhang, Ling, Lutterbach, Bart A, Pelletier, Marc R, Philippar, Ulrike, Siliphaivanh, Phieng, Witter, David, Kirschmeier, Paul, Bishop, W Robert, Hicklin, Daniel, Gilliland, D Gary, Jayaraman, Lata, Zawel, Leigh, Fawell, Stephen, Samatar, Ahmed A

“…The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway…”
Get more information

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms by Tong, Ling, Yu, Wensheng, Chen, Lei, Selyutin, Oleg, Dwyer, Michael P, Nair, Anilkumar G, Mazzola, Robert, Kim, Jae-Hun, Sha, Deyou, Yin, Jingjun, Ruck, Rebecca T, Davies, Ian W, Hu, Bin, Zhong, Bin, Hao, Jinglai, Ji, Tao, Zan, Shuai, Liu, Rong, Agrawal, Sony, Xia, Ellen, Curry, Stephanie, McMonagle, Patricia, Bystol, Karin, Lahser, Frederick, Carr, Donna, Rokosz, Laura, Ingravallo, Paul, Chen, Shiying, Feng, Kung-I, Cartwright, Mark, Asante-Appiah, Ernest, Kozlowski, Joseph A

“…We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a…”
Get full text

Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors by Fischmann, Thierry O, Smith, Catherine K, Mayhood, Todd W, Myers, Joseph E, Reichert, Paul, Mannarino, Anthony, Carr, Donna, Zhu, Hugh, Wong, Jesse, Yang, Rong-Sheng, Le, Hung V, Madison, Vincent S

“…MEK1 is a member of the MAPK signal transduction pathway that responds to growth factors and cytokines. We have determined that the kinase domain spans…”
Get full text

Biological Effects and Mechanism of Action of Farnesyl Transferase Inhibitors by Ashar, Hena R, Armstrong, Lydia, James, Linda J, Carr, Donna M, Gray, Kimberley, Taveras, Arthur, Doll, Ronald J, Bishop, W. Robert, Kirschmeier, Paul T

Get full text

The impact of curricular changes on BSCN students' clinical learning outcomes by Landeen, Janet, Carr, Donna, Culver, Kirsten, Martin, Lynn, Matthew-Maich, Nancy, Noesgaard, Charlotte, Beney-Gadsby, Larissa

“…Ongoing curricular renewal is a necessary phenomenon in nursing education to align learning with ever-changing professional practice demands. The McMaster…”
Get full text

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors by Moschos, Stergios J, Sullivan, Ryan J, Hwu, Wen-Jen, Ramanathan, Ramesh K, Adjei, Alex A, Fong, Peter C, Shapira-Frommer, Ronnie, Tawbi, Hussein A, Rubino, Joseph, Rush, 3rd, Thomas S, Zhang, Da, Miselis, Nathan R, Samatar, Ahmed A, Chun, Patrick, Rubin, Eric H, Schiller, James, Long, Brian J, Dayananth, Priya, Carr, Donna, Kirschmeier, Paul, Bishop, W Robert, Deng, Yongqi, Cooper, Alan, Shipps, Gerald W, Moreno, Blanca Homet, Robert, Lidia, Ribas, Antoni, Flaherty, Keith T

“…Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors…”
Get full text

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A by Asante-Appiah, Ernest, Liu, Rong, Curry, Stephanie, McMonagle, Patricia, Agrawal, Sony, Carr, Donna, Rokosz, Laura, Lahser, Frederick, Bystol, Karin, Chase, Robert, Black, Stuart, Ferrari, Eric, Ingravallo, Paul, Tong, Ling, Yu, Wensheng, Kozlowski, Joseph

“…Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a…”
Get full text

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions by Yu, Wensheng, Tong, Ling, Selyutin, Oleg, Chen, Lei, Hu, Bin, Zhong, Bin, Hao, Jinglai, Ji, Tao, Zan, Shuai, Yin, Jingjun, Ruck, Rebecca T, Curry, Stephanie, McMonagle, Patricia, Agrawal, Sony, Rokosz, Laura, Carr, Donna, Ingravallo, Paul, Bystol, Karin, Lahser, Frederick, Liu, Rong, Chen, Shiying, Feng, Kung-I, Cartwright, Mark, Asante-Appiah, Ernest, Kozlowski, Joseph A

“…We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated…”
Get full text

Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase by Deng, Yongqi, Shipps, Gerald W, Cooper, Alan, English, Jessie M, Annis, D. Allen, Carr, Donna, Nan, Yang, Wang, Tong, Zhu, Hugh Y, Chuang, Cheng-Chi, Dayananth, Priya, Hruza, Alan W, Xiao, Li, Jin, Weihong, Kirschmeier, Paul, Windsor, William T, Samatar, Ahmed A

“…An affinity-based mass spectrometry screening technology was used to identify novel binders to both nonphosphorylated and phosphorylated ERK2. Screening of…”
Get full text

Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors by Zhu, Hugh Y., Desai, Jagdish, Deng, Yongqi, Cooper, Alan, Wang, James, Shipps, Jerry, Samatar, Ahmed, Carr, Donna, Windsor, William

“…[Display omitted] Starting from weak μM hits identified through affinity based Automated Ligand Identification System (ALIS) screenings, double digit nM…”
Get full text

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology by Boga, Sobhana Babu, Alhassan, Abdul-Basit, Cooper, Alan B., Doll, Ronald, Shih, Neng-Yang, Shipps, Gerald, Deng, Yongqi, Zhu, Hugh, Nan, Yang, Sun, Robert, Zhu, Liang, Desai, Jagdish, Patel, Mehul, Muppalla, Kiran, Gao, Xiaolei, Wang, James, Yao, Xin, Kelly, Joseph, Gudipati, Subrahmanyam, Paliwal, Sunil, Tsui, Hon-Chung, Wang, Tong, Sherborne, Bradley, Xiao, Li, Hruza, Alan, Buevich, Alexei, Zhang, Li-Kang, Hesk, David, Samatar, Ahmed A., Carr, Donna, Long, Brian, Black, Stuart, Dayananth, Priya, Windsor, William, Kirschmeier, Paul, Bishop, Robert

“…[Display omitted] •Discovery of potent, selective and orally bioavailable ERK inhibitor for oncology.•Synthesis of tert 3-(S)thiomethyl pyrrolidine based ERK…”
Get full text

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology by Boga, Sobhana Babu, Deng, Yongqi, Zhu, Liang, Nan, Yang, Cooper, Alan B., Shipps, Gerald W., Doll, Ronald, Shih, Neng-Yang, Zhu, Hugh, Sun, Robert, Wang, Tong, Paliwal, Sunil, Tsui, Hon-Chung, Gao, Xiaolei, Yao, Xin, Desai, Jagdish, Wang, James, Alhassan, Abdul Basit, Kelly, Joseph, Patel, Mehul, Muppalla, Kiran, Gudipati, Subrahmanyam, Zhang, Li-Kang, Buevich, Alexei, Hesk, David, Carr, Donna, Dayananth, Priya, Black, Stuart, Mei, Hong, Cox, Kathleen, Sherborne, Bradley, Hruza, Alan W., Xiao, Li, Jin, Weihong, Long, Brian, Liu, Gongjie, Taylor, Stacey A., Kirschmeier, Paul, Windsor, William T., Bishop, Robert, Samatar, Ahmed A.

“…The emergence and evolution of new immunological cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat cancer. Toward…”
Get full text

Affinity Selection–Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor by Walker, Scott S, Degen, David, Nickbarg, Elliott, Carr, Donna, Soriano, Aileen, Mandal, Mihir, Painter, Ronald E, Sheth, Payal, Xiao, Li, Sher, Xinwei, Murgolo, Nicholas, Su, Jing, Olsen, David B, Ebright, Richard H, Young, Katherine

“…The growing prevalence of drug resistant bacteria is a significant global threat to human health. The antibacterial drug rifampin, which functions by…”
Get full text